Cardiol Therapeutics Inc
TSX:CRDL

Watchlist Manager
Cardiol Therapeutics Inc Logo
Cardiol Therapeutics Inc
TSX:CRDL
Watchlist
Price: 1.81 CAD -3.21%
Market Cap: 147.7m CAD
Have any thoughts about
Cardiol Therapeutics Inc?
Write Note
CRDL
/
Income Statement
/
Non-Reccuring Items

Cardiol Therapeutics Inc
Non-Reccuring Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cardiol Therapeutics Inc
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
Cardiol Therapeutics Inc
TSX:CRDL
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Canopy Growth Corp
TSX:WEED
Non-Reccuring Items
-CA$91.6m
CAGR 3-Years
46%
CAGR 5-Years
N/A
CAGR 10-Years
-77%
Sundial Growers Inc
NASDAQ:SNDL
Non-Reccuring Items
-CA$116.8m
CAGR 3-Years
2%
CAGR 5-Years
-130%
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Non-Reccuring Items
-$69.4m
CAGR 3-Years
34%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Non-Reccuring Items
$2.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Curaleaf Holdings Inc
CNSX:CURA
Non-Reccuring Items
-$164.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Cardiol Therapeutics Inc
Glance View

Market Cap
147.7m CAD
Industry
Pharmaceuticals

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory therapies for cardiovascular disease (CVD). The company is headquartered in Oakville, Ontario and currently employs 11 full-time employees. The company went IPO on 2018-12-20. The firm's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the Food and Drug Administration (FDA) for its investigational new drug (IND) application for a Phase II international trial that investigates the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which is a common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure.

CRDL Intrinsic Value
0.73 CAD
Overvaluation 60%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.